InventisBio
Dr. Wang has over 20 years of experience in pharmaceutical industry, working in Schering-Plough and Merck & Co. in preclinical oncology drug discovery and development. He graduated from Shanghai Medical University (Fudan University School of Pharmacy) and earned his Ph.D. in Pharmacology from the State University of New York at Stony Brook. He completed postdoctoral work at Baylor College of Medicine. Dr. Wang received two Schering-Plough President Awards for his contribution in drug discovery, and has published numerous patents, publications, meeting abstracts, and book chapters.
This person is not in any offices
InventisBio
Yifang Biotechnology (Shanghai) Co., Ltd. is an entrepreneurial biomedical company established in 2013. It is committed to the research and development of new drugs in the fields of the tumor, tumor immunity, and metabolism. The company's product pipeline includes lung cancer, breast cancer, tumor immunity, and gout, etc. Small molecule drug candidates for targeted therapy in the field, and the company is also actively developing drugs for other tumor and immune tumor targets.